Last reviewed · How we verify
Drug:JS001, Intravenous infusion — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Drug:JS001, Intravenous infusion (Drug:JS001, Intravenous infusion) — Shanghai Junshi Bioscience Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Drug:JS001, Intravenous infusion TARGET | Drug:JS001, Intravenous infusion | Shanghai Junshi Bioscience Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Drug:JS001, Intravenous infusion CI watch — RSS
- Drug:JS001, Intravenous infusion CI watch — Atom
- Drug:JS001, Intravenous infusion CI watch — JSON
- Drug:JS001, Intravenous infusion alone — RSS
Cite this brief
Drug Landscape (2026). Drug:JS001, Intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-js001-intravenous-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab